<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622869</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001H2304</org_study_id>
    <secondary_id>2007-001821-85</secondary_id>
    <nct_id>NCT00622869</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients</brief_title>
  <acronym>RAD</acronym>
  <official_title>A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This trial was designed to address important issues that impact recipients of liver
      allografts as well as clinicians, ie, renal function, reduction or discontinuation of
      tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus
      (HCV) positive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 24-month study consisted of a screening period, a baseline period (3 to 7 days
      post-transplantation) followed by a run-in period that ended on the day of randomization at
      30 days (± 5 days) post-transplantation. Patients were screened for eligibility prior to
      liver transplantation. Patients who had undergone successful liver transplantation were
      initiated on a tacrolimus-based regimen that included corticosteroids and entered the
      baseline period (between 3 and 7 days post-transplantation). At 30 (± 5) days
      post-transplantation, patients who met additional randomization inclusion/exclusion criteria
      were randomized into the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure From Randomization to Month 12</measure>
    <time_frame>Randomization to Month 12</time_frame>
    <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Composite Efficacy Failure From Randomization to Month 24</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Treated Biopsy Proven Acute Rejection (tBPAR) at Months 12 and 24</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>tBPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3, which was treated with anti-rejection therapy. Liver biopsies were collected for all cases of suspected acute rejection preferably within 24 hours, at the latest within 48 hours, whenever clinically possible. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of tBPAR were estimated with a Kaplan-Meier product-limit formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function From Randomization to Months 12 and 24</measure>
    <time_frame>Randomization to Month 24</time_frame>
    <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.
The changes in renal function were analyzed via analysis of covariance (ANCOVA) with treatment, pre-transplant hepatitis C virus status and randomization eGFR as covariates. Based on these ANCOVA analyses, the least-squares mean and standard errors of change were reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">719</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control dose tacrolimus + corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (reduced tacrolimus)</intervention_name>
    <description>After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (tacrolimus elimination)</intervention_name>
    <description>After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.</description>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (tacrolimus control)</intervention_name>
    <description>Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.</description>
    <arm_group_label>Tacrolimus control</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (reduced tacrolimus)</intervention_name>
    <description>Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <other_name>RAD-001</other_name>
    <other_name>Zortress</other_name>
    <other_name>Certican</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (tacrolimus elimination)</intervention_name>
    <description>Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.</description>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <other_name>RAD-001</other_name>
    <other_name>Zortress</other_name>
    <other_name>Certican</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <arm_group_label>Tacrolimus elimination</arm_group_label>
    <arm_group_label>Tacrolimus control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent and adhere to study
             regimen.

          -  Recipients who are 18-70 years of age of a primary liver transplant from a deceased
             donor.

          -  Recipients who have been initiated on an immunosuppressive regimen that contains
             corticosteroids and tacrolimus, 3-7 days post-transplantation.

          -  Confirmed recipient hepatitis C virus (HCV) status at Screening (either by antibody or
             by PCR (polymerase chain reaction).

          -  Allograft is functioning at an acceptable level by the time of randomization as
             defined by protocol specific laboratory values.

          -  Abbreviated Modification of Diet in Renal Disease estimated glomerular filtration rate
             (MDRD eGFR) ≥ 30 mL/min/1.73m2. Results obtained within 5 days prior to randomization
             are acceptable, however, no sooner than Day 25 post-transplantation.

          -  Verification of at least 1 tacrolimus trough level of ≥ 8 ng/mL in the week prior to
             randomization. Investigators should make adjustments in tacrolimus dosing to continue
             to target trough levels above 8 ng/mL prior to randomization.

        Exclusion Criteria

          -  Patients who are recipients of multiple solid organ or islet cell tissue transplants,
             or have previously received an organ or tissue transplant. Patients who have a
             combined liver-kidney transplant.

          -  Recipients of a liver from a living donor, or of a split liver.

          -  History of malignancy of any organ system within the past 5 years whether or not there
             is evidence of local recurrence or metastases, other than non-metastatic basal or
             squamous cell carcinoma of the skin, or HCC (hepatocellular carcinoma) (see next
             criteria).

          -  Hepatocellular carcinoma that does not fulfill Milan criteria (1 nodule ≤ 5 cm, 2-3
             nodules all &lt; 3 cm) at the time of transplantation as per explant histology of the
             recipient liver.

          -  Any use of antibody induction therapy.

          -  Patients with a known hypersensitivity to the drugs used on study or their class, or
             to any of the excipients.

          -  Patients who are recipients of ABO incompatible transplant grafts.

          -  Recipients of organs from donors who test positive for Hepatitis B surface antigen or
             HIV are excluded.

          -  Patients who have any surgical or medical condition, which in the opinion of the
             investigator, might significantly alter the absorption, distribution, metabolism and
             excretion of study drug.

          -  Women of child-bearing potential (WOCBP).

          -  Patients with any history of coagulopathy or medical condition requiring long-term
             anticoagulation which would preclude liver biopsy after transplantation. (Low dose
             aspirin treatment or interruption of chronic anticoagulant is allowed).

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-2312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <zip>C1107BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>C2000DSR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>W3400ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blumenau</city>
        <state>SC</state>
        <zip>89010-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadanonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo</city>
        <state>País Vasco</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>ED16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>everolimus</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>renal function</keyword>
  <keyword>MDRD formula</keyword>
  <keyword>progression of fibrosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Everolimus + Reduced Tacrolimus</title>
          <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus Elimination</title>
          <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
        </group>
        <group group_id="P3">
          <title>Tacrolimus Control Arm</title>
          <description>Control dose tacrolimus + corticosteroids.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft Loss</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus + Reduced Tacrolimus</title>
          <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus Elimination</title>
          <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
        </group>
        <group group_id="B3">
          <title>Tacrolimus Control Arm</title>
          <description>Control dose tacrolimus + corticosteroids.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="243"/>
            <count group_id="B4" value="719"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="9.2"/>
                    <measurement group_id="B2" value="53.2" spread="10.8"/>
                    <measurement group_id="B3" value="54.5" spread="8.7"/>
                    <measurement group_id="B4" value="53.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Composite Efficacy Failure From Randomization to Month 12</title>
        <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
        <time_frame>Randomization to Month 12</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control Arm</title>
            <description>Control dose tacrolimus + corticosteroids.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure From Randomization to Month 12</title>
          <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Composite Efficacy Failure From Randomization to Month 24</title>
        <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control Arm</title>
            <description>Control dose tacrolimus + corticosteroids.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Composite Efficacy Failure From Randomization to Month 24</title>
          <description>Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death.
The incidence rates of composite efficacy failure were estimated with a Kaplan-Meier product-limit formula.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Treated Biopsy Proven Acute Rejection (tBPAR) at Months 12 and 24</title>
        <description>tBPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3, which was treated with anti-rejection therapy. Liver biopsies were collected for all cases of suspected acute rejection preferably within 24 hours, at the latest within 48 hours, whenever clinically possible. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of tBPAR were estimated with a Kaplan-Meier product-limit formula.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control Arm</title>
            <description>Control dose tacrolimus + corticosteroids.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Treated Biopsy Proven Acute Rejection (tBPAR) at Months 12 and 24</title>
          <description>tBPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3, which was treated with anti-rejection therapy. Liver biopsies were collected for all cases of suspected acute rejection preferably within 24 hours, at the latest within 48 hours, whenever clinically possible. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, they received a graft re-transplant, or they died.
The incidence rates of tBPAR were estimated with a Kaplan-Meier product-limit formula.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="19.9"/>
                    <measurement group_id="O3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function From Randomization to Months 12 and 24</title>
        <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.
The changes in renal function were analyzed via analysis of covariance (ANCOVA) with treatment, pre-transplant hepatitis C virus status and randomization eGFR as covariates. Based on these ANCOVA analyses, the least-squares mean and standard errors of change were reported.</description>
        <time_frame>Randomization to Month 24</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Reduced Tacrolimus</title>
            <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Elimination</title>
            <description>Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.</description>
          </group>
          <group group_id="O3">
            <title>Tacrolimus Control Arm</title>
            <description>Control dose tacrolimus + corticosteroids.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function From Randomization to Months 12 and 24</title>
          <description>Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m^2) = 186.3*(C^-1.154)*(A^-0.203)*G*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.
The changes in renal function were analyzed via analysis of covariance (ANCOVA) with treatment, pre-transplant hepatitis C virus status and randomization eGFR as covariates. Based on these ANCOVA analyses, the least-squares mean and standard errors of change were reported.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>mL/min/1.73m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (N=244, 231, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.54"/>
                    <measurement group_id="O2" value="-1.51" spread="1.58"/>
                    <measurement group_id="O3" value="-10.73" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (N=245, 231, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.94" spread="1.53"/>
                    <measurement group_id="O2" value="-4.19" spread="1.58"/>
                    <measurement group_id="O3" value="-14.60" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were followed until resolution or judged permanent. Serious AEs occurring after transplantation, until 30 days after study medication (SM) discontinuation, or &gt; 4 weeks after study discontinuation if related to SM were reported.</time_frame>
      <desc>Safety population: All patients who received at least 1 dose of randomized study medication.
Adverse events up to Month 24 were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus + Reduced Tacrolimus</title>
          <description>Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus Elimination</title>
          <description>Low dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids</description>
        </group>
        <group group_id="E3">
          <title>Tacrolimus Control Arm</title>
          <description>Control dose tacrolimus + corticosteroids</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hepato-lenticular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gingival erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spigelian hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary cast syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholangitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Overlap syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumonia herpes viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sinusitis aspergillus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Biliary anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Complications of transplanted heart</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Complications of transplanted liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Graft dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypoinsulinaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver graft loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus malnutrition-related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Benign duodenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Castleman's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastric sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Retroperitoneal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Critical illness polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Radiculitis brachial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ureteric fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholestatic pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="205" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

